BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/2/2023 9:29:03 AM | Browse: 352 | Download: 1363
 |
Received |
|
2023-05-06 15:44 |
|
Peer-Review Started |
|
2023-05-06 15:47 |
|
First Decision by Editorial Office Director |
|
2023-05-17 06:56 |
|
Return for Revision |
|
2023-05-17 06:56 |
|
Revised |
|
2023-05-24 06:05 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-07-04 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-07-05 17:32 |
|
Articles in Press |
|
2023-07-05 17:32 |
|
Edit the Manuscript by Language Editor |
|
2023-07-07 10:01 |
|
Typeset the Manuscript |
|
2023-07-26 07:10 |
|
Publish the Manuscript Online |
|
2023-08-02 09:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Basic Study |
| Article Title |
MiR-204-3p overexpression inhibits gastric carcinoma cells proliferation via inhibiting the MAPK pathway and RIP1/MLK1 necroptosis pathway to promote apoptosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xia Li, Joanna J Tibenda, Yi Nan, Shi-Cong Huang, Na Ning, Guo-Qing Chen, Yu-Hua Du, Ya-Ting Yang, Fan-Di Meng and Ling Yuan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ningxia Natural Science Foundation |
2022AAC03144 |
|
| Corresponding Author |
Ling Yuan, PhD, Professor, College of Pharmacy, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080017@nxmu.edu.cn |
| Key Words |
miR-204-3p; Gastric carcinoma; MAPK signaling pathway; Apoptosis; Necroptosis |
| Core Tip |
Gastric carcinoma (GC) is a global health problem that seriously endangers human life, therefore, it is important to find effective treatment targets. In this regard, microRNAs (miRNAs) have emerged as a promising therapeutic strategy. Studies have shown that miRNAs regulated signaling pathways, acting as tumor suppressors or tumor promoters. In this paper, we first verified the inhibitory effect of miR-204-3p overexpression on GC cells through in vitro and in vivo experiments. Simultaneously, miR-204-3p overexpression induced GC cells apoptosis by inhibiting the MAPK pathway, as well as inhibiting the necroptosis. Thus, miR-204-3p may represent a new potential therapeutic target for GC. |
| Publish Date |
2023-08-02 09:29 |
| Citation |
Li X, Tibenda JJ, Nan Y, Huang SC, Ning N, Chen GQ, Du YH, Yang YT, Meng FD, Yuan L. MiR-204-3p overexpression inhibits gastric carcinoma cells proliferation via inhibiting the MAPK pathway and RIP1/MLK1 necroptosis pathway to promote apoptosis. World J Gastroenterol 2023; 29(29): 4542-4556 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i29/4542.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i29.4542 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
